ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ$11.87
Market Cap
$1.15B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
39 of 924
Rank in Industry
29 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SPRY Insider Trading Activity
SPRY Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $13,289,410 | 3 | 3 |
Sells | $93,546,043 | 88 | 97 |
Related Transactions
| RA CAPITAL MANAGEMENT, L.P. | 3 | $13.29M | 0 | $0 | $13.29M | |
| Scott Kathleen D. | Chief Financial Officer | 0 | $0 | 2 | $400,000 | $-400,000 |
| Karas Eric | Chief Commercial Officer | 0 | $0 | 4 | $420,423 | $-420,423 |
| Dorsey Brian | Chief Operating Officer | 0 | $0 | 4 | $1.63M | $-1.63M |
| Shawver Laura | director | 0 | $0 | 7 | $4.42M | $-4.42M |
| Chakma Justin | Chief Business Officer | 0 | $0 | 11 | $7.09M | $-7.09M |
| Flynn James E | 10 percent owner | 0 | $0 | 2 | $10.14M | $-10.14M |
| ORBIMED ADVISORS LLC | director | 0 | $0 | 4 | $12.59M | $-12.59M |
| Thompson Peter A. | director | 0 | $0 | 4 | $12.59M | $-12.59M |
| Lowenthal Richard E | PRESIDENT AND CEO | 0 | $0 | 26 | $22.14M | $-22.14M |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | 0 | $0 | 26 | $22.14M | $-22.14M |
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Insider Activity of ARS Pharmaceuticals, Inc.
Over the last 12 months, insiders at ARS Pharmaceuticals, Inc. have bought $13.29M and sold $93.55M worth of ARS Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ARS Pharmaceuticals, Inc. have bought $25.62M and sold $33.02M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $13.29M.
The last purchase of 505,954 shares for transaction amount of $4.95M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
List of Insider Buy and Sell Transactions, ARS Pharmaceuticals, Inc.
| 2025-03-06 | Sale | Shawver Laura | director | 49,600 0.0524% | $11.21 | $556,046 | +8.33% | |
| 2025-03-05 | Sale | Shawver Laura | director | 400 0.0004% | $11.00 | $4,400 | +6.07% | |
| 2025-02-03 | Sale | Shawver Laura | director | 50,000 0.0486% | $12.31 | $615,565 | -5.40% | |
| 2025-01-06 | Sale | Shawver Laura | director | 50,000 0.0511% | $11.10 | $555,065 | +7.31% | |
| 2024-12-17 | Sale | Tanimoto Sarina | CHIEF MEDICAL OFFICER | 100,000 0.1035% | $11.67 | $1.17M | -2.30% | |
| 2024-12-17 | Sale | Lowenthal Richard E | PRESIDENT AND CEO | 100,000 0.1035% | $11.67 | $1.17M | -2.30% | |
| 2024-12-13 | Sale | Chakma Justin | Chief Business Officer | 27,272 0.0282% | $12.06 | $328,969 | -3.03% | |
| 2024-12-12 | Sale | Chakma Justin | Chief Business Officer | 117,333 0.1186% | $12.27 | $1.44M | -8.62% | |
| 2024-12-12 | Sale | Dorsey Brian | Chief Operating Officer | 25,000 0.0253% | $12.30 | $307,433 | -8.62% | |
| 2024-12-11 | Sale | Dorsey Brian | Chief Operating Officer | 15,000 0.0154% | $12.43 | $186,426 | -5.09% | |
| 2024-12-10 | Sale | Tanimoto Sarina | CHIEF MEDICAL OFFICER | 100,000 0.1038% | $13.16 | $1.32M | -9.34% | |
| 2024-12-10 | Sale | Lowenthal Richard E | PRESIDENT AND CEO | 100,000 0.1038% | $13.16 | $1.32M | -9.34% | |
| 2024-12-10 | Sale | Chakma Justin | Chief Business Officer | 50,000 0.0519% | $13.15 | $657,625 | -9.34% | |
| 2024-12-06 | Sale | Chakma Justin | Chief Business Officer | 50,000 0.0517% | $14.23 | $711,615 | -16.12% | |
| 2024-12-05 | Sale | Chakma Justin | Chief Business Officer | 49,640 0.0521% | $14.13 | $701,642 | -16.00% | |
| 2024-12-04 | Sale | Shawver Laura | director | 14,772 0.0146% | $13.75 | $203,109 | -18.45% | |
| 2024-12-04 | Sale | Chakma Justin | Chief Business Officer | 45,000 0.0452% | $13.95 | $627,944 | -18.45% | |
| 2024-12-04 | Sale | Karas Eric | Chief Commercial Officer | 6,283 0.0063% | $14.00 | $87,962 | -18.45% | |
| 2024-12-03 | Sale | Shawver Laura | director | 87,984 0.0888% | $13.26 | $1.17M | -13.41% | |
| 2024-12-03 | Sale | Chakma Justin | Chief Business Officer | 45,000 0.0452% | $13.19 | $593,402 | -13.41% |
Total: 121
*Gray background shows transactions not older than one year
Insider Historical Profitability
132.88%
| RA CAPITAL MANAGEMENT, L.P. | 9958073 10.2465% | $118.2M | 5 | 0 | +131.88% | |
| ORBIMED ADVISORS LLC | director | 0 0% | $0 | 1 | 4 | |
| Thompson Peter A. | director | 0 0% | $0 | 1 | 4 | |
| Fitzpatrick Alexander A | Chief Legal Officer | 89227 0.0918% | $1.06M | 2 | 0 | +133.38% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,217,280 | 112 | 46.33% | $1.29B | |
$54,590,806 | 65 | 21.84% | $1.23B | |
$1,101,324,300 | 58 | 37.37% | $1.3B | |
$571,084,134 | 44 | 4.33% | $988.55M | |
$100,002,191 | 42 | 21.48% | $1.22B |
SPRY Institutional Investors: Active Positions
| Increased Positions | 100 | +67.57% | 13M | +20.54% |
| Decreased Positions | 60 | -40.54% | 5M | -7.84% |
| New Positions | 41 | New | 3M | New |
| Sold Out Positions | 18 | Sold Out | 1M | Sold Out |
| Total Postitions | 188 | +27.03% | 72M | +12.71% |
SPRY Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ra Capital Management, L.P. | $113,823.00 | 11.2% | 10.86M | 0 | 0% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $110,194.00 | 10.84% | 10.51M | -563,270 | -5.08% | 2024-12-31 |
| Orbimed Advisors Llc | $86,864.00 | 8.55% | 8.29M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $47,941.00 | 4.72% | 4.57M | +328,517 | +7.74% | 2024-12-31 |
| Sr One Capital Management, Lp | $42,055.00 | 4.14% | 4.01M | 0 | 0% | 2024-12-31 |
| Alliancebernstein L.P. | $40,670.00 | 4% | 3.88M | +4M | +5,168.44% | 2024-12-31 |
| Vanguard Group Inc | $36,313.00 | 3.57% | 3.46M | +115,656 | +3.45% | 2024-12-31 |
| State Street Corp | $28,819.00 | 2.84% | 2.75M | +700,359 | +34.17% | 2024-12-31 |
| Franklin Resources Inc | $20,713.00 | 2.04% | 1.98M | -860,840 | -30.34% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $13,139.00 | 1.29% | 1.25M | +1M | +902.98% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.